Enar Recalde

Radiation Oncologist at Vall d’Hebron Hospital. Gynecologic tumors, PROMs and Quality of Life. | 📲are my own | #Radonc

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

💡 Profesionales de #VHIO participaron en #ESTRO2026, una de las principales citas internacionales en oncología radioterápica.

👩‍⚕️ Laia Humbert-Vidan, investigadora del Grupo de Oncología Radioterápica del VHIO, y @SaraGutierrezEn, jefa del Laboratorio de Genética Traslacional, presentaron aportaciones clave en este ámbito.

➡️ https://t.co/JMzoMHT1JT

[Dr. Nina Niu Sanford @NiuSanford]

Impressive daraxonrasib data.

From RT standpt, if RAS inhibition meaningfully prolongs dz control, local progression = more relevant

Future trials should test consolidative ablative RT in pts responding to darax (potentially leveraging RAS-mediated radiosens) #ASCO26 @OncoAlert

[Enar Recalde @E_revir]

Excited to continue sharing our work on #PROMs in gynecologic RT. Apart from CTCAE, can we use patient reported symptoms for constraint optimization? What our patients report is consistent with EMBRACE II data. So…probably yes! #ESTRO26

[Enar Recalde @E_revir]

Such an important message! Patient-centered care is also patient-centered research (from design!) #ESTRO26 #ESTRO2026

[OncoAlert @OncoAlert]

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨
Five-Year Follow-Up of the SABR 5 Trial: Primary Toxicity Analysis of Stereotactic Ablative Radiotherapy for Up to Five Oligometastases Presenter Robert Olson 🇨🇦

SABR-5 is a population-based phase II trial evaluating long-term toxicity of SABR for patients with up to five oligometastases. Among 380 patients treated across a provincial program, five-year follow-up showed low rates of high-grade toxicity, with no late emergence of grade ≥4 events. Most late toxicities were low grade and often persistent rather than new. These findings provide reassurance regarding the long-term safety of SABR in routine clinical practice.

#RadOnc
@ESTRO_RT
@yasemin09896924
@LindaMrissa
@christian_roenn
@Valeriadionisi
@gerryhanna
@clchiang_hk
@mtugceyilmaz
@B_Tomasik
@gmpetrianni
@CiroFranzese1
@Atem84
@piet_ost
@brachyexpert
@BlanceS90
@The_PT_Explorer
@BarbaraJereczek
@Mat_Guc
@ZilliThomas
@AnnaKirby17
@PBlanchardMD
@achoud72

Pinging OA faculty
@MKnoll_MD
@_ShankarSiva
@Icro_Meattini
@seanmmcbride
@NiuSanford
@nataliagandur
@acampsmalea
@to_be_elizabeth

[Piet Ost @piet_ost]

1/7 🧵 New in @LancetOncology: we built a Delphi consensus on primary endpoints for MDT trials in oligometastatic cancer — because the endpoints we've been using were designed for drugs, not for ablation.
On behalf of the EORTC–ESTRO OligoCare consortium.

[Enar Recalde @E_revir]

A challenging year of learning 📚in gyne rad onc—really happy with the effort! Our abstracts accepted at #ESTRO2026. Thanks to the team and to our patients 🫂 Looking forward to Stockholm! #radonc #gyneonc #cervixcancer #ovariancancer

[Dr Rishabh Jain @DrRishabhOnco]

💡 Pancreatic cancer’s big question: Which neoadjuvant is best? PREOPANC-2 says… both.

👥 Population
• 369 pts | Resectable / borderline PDAC
• Phase III | 19 Dutch centers

🧪 Arms
1️⃣ FOLFIRINOX (8 cycles) ➡️ Surgery (no adjuvant)
2️⃣ Gemcitabine-CRT (3 cycles + RT) ➡️ Surgery ➕ Adjuvant Gem

📊 Results (mITT)
🕰️ Median OS: 21.9 mo (FFX) vs 21.3 mo (CRT) | HR 0.88, p=0.32
📉 3-yr OS: 36% vs 33%
⏳ PFS: 12.1 vs 11.9 m

🔪 R0 resection: 60% vs 67% | pCR: 10% vs
5%

⚠️ ≥G3 AEs: 67% vs 60%

☠️ Tx-related deaths: 2 vs 1

💡 Takeaway
No OS advantage for FFX over Gem-CRT. Both remain valid options → tailor choice to fitness, toxicity profile, & patient preference.

📖 Janssen et al. Lancet Oncol 2025
🔗 https://t.co/x5UNRM8D7M

#OncoTwitter #PancreaticCancer #MedTwitter
@OncoAlert @esmo_open @myESMO @ASCO @LancetOncol

[Drew Moghanaki @DrewMoghanaki]

If you’re a fan of radiation oncology and struggling to figure out why more people don’t celebrate the cancer treatments we deliver, then this editorial might be for you. @IJROBP @sueyom @NehaVapiwala

https://t.co/sa8vmX1aKx

[ESTRO @ESTRO_RT]

🟠Cristina Gutiérrez shares the inspiring case of a young mother diagnosed with metastatic #breastcancer during pregnancy.
🎥 Watch her testimony & discover how #radiotherapy can make a difference in even the most challenging situations.
@WorldRTDay #OneVoiceForRadiotherapy #WRAD

[Irish Research Radiation Oncology Group @IRROGTrials]

1st pt in Ireland randomised on the oligomet breast cancer TAORMINA trial in St. Luke's Hospital.

Well done to all involved.

Thsi trial offers pts the chance to have high dose radiation to discrete areas of cancer spread on this important trial!

#breastoncology #clinicaltrials

[Marcelino Hermida López @marslain]

Irradiación corporal total con radioterapia volumétrica modulada (VMAT-TBI) para pacientes pediátricos en Hospital Vall d'Hebron @vallhebron

https://t.co/cRYG3DEwsV

[Dr Amol Akhade @SuyogCancer]

Excellent summary slides for current evidence for pancreatic cancer treatment . Useful for quick reference. @asco #asco25 taken from talk by Dr Brian Wolpin 👍@OncoAlert @brunolarvol

[NEJM @NEJM]

Presented at #ASCO25:

A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results: https://t.co/j3kWJDjuVz

@ASCO

[TMC Radiation Oncology @RadOncTMC]

Honored to share highlights of @ReenaEngineer’s presentation of POLCAGB phase III trial at #ASCO2025, a game changer for locally advanced gallbladder cancer
Neoadj CRT vs CT alone:
🌟 Nearly doubled mOS (21.8 vs 10.1 months)
🌟 Significantly improved R0 resection (51.6% vs 29.7%)

[Giulia Marvaso @GiuliaMarvaso84]

Radiotherapy is not visible enough to patients—and what they don’t see, they may fear.
It’s time to strengthen patient advocacy and engagement. Let’s make RT more transparent, accessible, and empowering. @BarbaraJereczek final remarks
#ESTRO25 #PatientEngagement #RTAwareness

[Enar Recalde @E_revir]

Soon sharing the patients views on RT effects — key to understanding the real impact of our treatments

[Enar Recalde @E_revir]

I hate talking about toxicity…but love #PROMs!
We’ve learned a lot after over a year developing our #ePROM 📲-based symptom monitoring program for #GynecologicCancer during #Radiotherapy

#ESTRO25

[Enar Recalde @E_revir]

@marslain @ferrandiz_carla @JHernando3 Thanks for the appreciation! We aimed to illustrate the complexity of initial management and relapse (R) scenarios

[Enar Recalde @E_revir]

Presenting 🗣️ our experience with radiotherapy for Merkel cell carcinoma at #ESTRO2025. A collaboration with #Dermathology and #MedOnc colleagues @ferrandiz_carla @JHernando3 #ESTRO25 #Radonc